Breaking News, Financial News

Covance

Revenues up, earnings down at Covance

Covance 2Q09

2Q Revenues: $466 million (+7%)

2Q Earnings: $43 million (-16%)

YTD Revenues: $907 million (+7%)

YTD Earnings: $83 million (-17%)

Comments: Early Development revenues dropped 6% in the quarter to $200 million, reflecting lower demand in toxicology services. Demand grew for clinical pharmacology, analytical chemistry and research services. Late-Stage Development revenues grew 19% to $266 million, driven by increases in demand for central lab services, as well as clinical development and commercialization services.

Sign up today for Contracting & Outsourcing 2009!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters